Company news

Allogene Therapeutics, Inc. news in 2024

Allogene Therapeutics, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Allogene Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

December 15, 2024

Allogene Therapeutics Acknowledges the Passing of Founding Board Member David Bonderman

December 11, 2024

Allogene Therapeutics Announces Participation in December Investor Conferences

November 18, 2024

Allogene Therapeutics Presents Preclinical Data for ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Disease at the American College of Rheumatology (ACR) Convergence

November 17, 2024

Allogene Therapeutics Reports Third Quarter 2024 Financial Results and Business Update

November 6, 2024

Allogene Therapeutics Announces Positive Phase 1 Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Patients with Advanced Renal Cell Carcinoma at SITC and IKCS

November 6, 2024

Allogene Therapeutics to Present New Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Adult Patients with CD70 Positive Advanced Renal Cell Carcinoma (RCC) at the International Kidney Cancer Symposium (IKCS) and Society for Immunothe...

November 4, 2024

Allogene Therapeutics Announces Participation in November Investor Conferences

November 3, 2024

Allogene Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update

October 29, 2024

Allogene Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ALLO-316, an AlloCAR T™ Investigational Product for Adult Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC)

October 28, 2024

Allogene Therapeutics Announces Participation in the Goldman Sachs Cell Therapy Day Conference

September 29, 2024

Allogene Therapeutics to Present Pre-Clinical Data Highlighting the Potential of ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Diseases, at the American College of Rheumatology (ACR) Convergence

September 25, 2024

Allogene Therapeutics Reports Second Quarter 2024 Financial Results and Business Update

August 6, 2024

Allogene Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update

July 30, 2024

Allogene Therapeutics Activates Three Community Cancer Centers as First Sites for the Pivotal Phase 2 ALPHA3 Trial Evaluating Cemacabtagene Ansegedleucel (cema-cel) as First Line (1L) Consolidation Treatment for Patients with Large B-Cell Lymphoma (LBCL)

June 30, 2024

Allogene Therapeutics Initiates Pivotal Phase 2 Trial Investigating Cemacabtagene Ansegedleucel (cema-cel), an Allogeneic CAR T Product, as Part of First Line Treatment for Patients with Large B-Cell Lymphoma (LBCL) Likely to Relapse

June 19, 2024

Allogene Therapeutics Announces Participation in the TD Cowen 5th Annual Oncology Innovation Summit

May 22, 2024

Allogene Therapeutics Reports First Quarter 2024 Financial Results and Business Update

May 12, 2024

Allogene Therapeutics Announces Pricing of $110 million Offering of Common Stock

May 12, 2024

Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update

May 5, 2024

Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal Cell Carcinoma

April 25, 2024

Allogene Therapeutics Announces Q2 Investor Conference Participation

April 8, 2024

Allogene Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update

March 13, 2024

Allogene Therapeutics and Arbor Biotechnologies Announce Global Gene Editing Licensing Agreement to Support Advancement of Next-Generation Allogeneic CAR T Platform in Autoimmune Disease

March 11, 2024

Allogene Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update

March 4, 2024

Allogene Therapeutics Announces Participation in the 44th Annual TD Cowen Health Care Conference

February 27, 2024

Allogene Therapeutics to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments Related to the December 2020 Formation of the Allogene Overland Biopharm Joint Venture in Asia

February 15, 2024

Allogene Therapeutics Announces 2024 Platform Vision to Redefine the Future of CAR T Led by ALPHA3, the Industry's First Pivotal Trial for Frontline Consolidation in Large B-Cell Lymphoma

January 3, 2024

Allogene Therapeutics and Foresight Diagnostics Announce Partnership to Develop MRD-based In-Vitro Diagnostic for Use in ALPHA3, the First Pivotal Trial for Frontline Consolidation in Large B-Cell Lymphoma

January 3, 2024

Allogene Therapeutics to Host Conference Call Previewing its 2024 Platform Vision and Present at the 42nd Annual J.P. Morgan Healthcare Conference

January 2, 2024

Calls in 2024

Decks in 2024